How can molecular abnormalities influence our clinical approach.

Area of Science:

• Oncology
• Genomics
• Translational Medicine

Background:

• Epithelial ovarian cancer (EOC) shows poor clinical outcomes despite diagnostic and therapeutic improvements over 30 years.
• Recent genomic studies highlight EOC's heterogeneity, with distinct molecular signatures within and across histotypes.

Purpose of the Study:

• To review molecular genetics of EOC.
• To discuss translation of genetic findings into clinical trials.
• To explore implications for patient stratification and personalized medicine.

Main Methods:

• Comprehensive review of multiple genomic studies on ovarian cancer.
• Emphasis on molecular abnormalities and their clinical applicability.
• Analysis of data to rationalize recent clinical trial designs.

Main Results:

• Molecular profiling identifies distinct EOC subsets with characteristic genomic aberrations, dysregulated pathways, and chemoresistance mechanisms.
• Genomic studies delineate molecular basis for diverse clinical behaviors, correlating with tumor histology and grade.
• Integrated 'omics' analyses yield potential biomarkers for novel therapeutics, patient stratification, and predicting clinical endpoints.

Conclusions:

• Understanding EOC's molecular landscape shifts clinical trials from empirical to rationalized, personalized paradigms.
• Personalized approaches aligning patient characteristics, biomarkers, and targeted therapies offer improved patient outcomes.
• Further validation of biomarkers is crucial for clinical relevance and successful translation in ovarian cancer trials.